|国家科技期刊平台
首页|期刊导航|中国临床药理学与治疗学|1例烟雾病合并子宫内膜异位症患者围手术期抗血小板药物调整及术后预防内异症复发药物选择的病例分析

1例烟雾病合并子宫内膜异位症患者围手术期抗血小板药物调整及术后预防内异症复发药物选择的病例分析OA北大核心CSTPCD

A case analysis of medication adjustments on a moyamoya disease patient with endometriosis by DAPT treatment during perioperative period and formulation of DIE postoperative recurrence prevention

中文摘要英文摘要

目的:探讨临床药师在烟雾病患者围术期个体化治疗与用药监护中的工作要点.方法:参与1例烟雾病合并子宫内膜异位症患者围术期双联抗血小板治疗的药物调整、围术期应用质子泵抑制剂及深部子宫内膜异位症术后预防复发方案的制订与用药监护.结果:通过对患者的个体化评估确定符合患者的双联抗血小板治疗在围术期停药方案,制订个体化的围术期应用质子泵抑制剂及深部子宫内膜异位症术后预防复发方案.结论:个体化用药方案的制订及用药监护是临床药师开展药学服务的切入点.

AIM:To explore the key points of per-sonalized treatment and medication monitoring by clinical pharmacists in the perioperative period of moyamoya disease patients with endometriosis.METHODS:This study showed a moyamoya disease patient with endometriosis who accepting dual an-tiplatelet therapy and how to adjust medication during the perioperative period.Besides,monitor-ing the use proton pump inhibitors in the perioper-ative period and the formulating a plan of DIE post-operative recurrence prevention are also our objec-tives.RESULTS:Through individualized assessment of the patient,a personalized medication adjust-ments for dual antiplatelet therapy was deter-mined.Individualized perioperative proton pump inhibitor regimen and postoperative prevention plan for endometriosis recurrence were developed.CONCLUSION:The development of individualized medication regimens and medication monitoring is the breakthrough point for clinical pharmacists to carry out pharmaceutical services.

罗莉婷;金经

复旦大学附属妇产科医院药学部,上海 200090||珠海市妇幼保健院药学部,珠海 519000,广东复旦大学附属妇产科医院药学部,上海 200090

临床医学

烟雾病子宫内膜异位症双联抗血小板预防复发

moyamoya diseaseendometriosisDAPTpreventing recurrence

《中国临床药理学与治疗学》 2024 (005)

495-500 / 6

2021年上海市"医苑新星"青年医学人才培养资助(076478684Q/2022-00033)

10.12092/j.issn.1009-2501.2024.05.003

评论